The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway.
Abstract
The mechanism of inhibition by apolipoprotein C of the uptake and degradation of triglyceride-rich lipoproteins from human plasma via the low density lipoprotein (LDL) receptor pathway was investigated in cultured human skin fibroblasts. Very low density lipoprotein (VLDL) density subfractions and intermediate density lipoprotein (IDL) with or without added exogenous recombinant apolipoprotein E-3 were used. Total and individual (C-I, C-II, C-III-1, and C-III-2) apoC molecules effectively inhibited apoE-3-mediated cell metabolism of the lipoproteins through the LDL receptor, with apoC-I being most effective. When the incubation was carried out with different amounts of exogenous apoE-3 and exogenous apoC, it was shown that the ratio of apoE-3 to apoC determined the uptake and degradation of VLDL. Excess apoE-3 overcame, at least in part, the inhibition by apoC. ApoC, in contrast, did not affect LDL metabolism. Neither apoA-I nor apoA-II, two apoproteins that do not readily associate with VLDL, had any effect on VLDL cell metabolism. The inhibition of VLDL and IDL metabolism cannot be fully explained by interference of association of exogenous apoE-3 with or displacement of endogenous apoE from the lipoproteins. IDL is a lipoprotein that contains both apoB-100 and apoE. By using monoclonal antibodies 4G3 and 1D7, which specifically block cell interaction by apoB-100 and apoE, respectively, it was possible to assess the effects of apoC on either apoprotein. ApoC dramatically de…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
ApoC1 is present at higher levels in ApoE2 and ApoE3 microglia-secreted lipoproteins.
“Apolipoprotein C1 (ApoC1) was found to be present at higher levels in ApoE2 and ApoE3 microglia secreted lipoproteins and is reported to inhibit binding of ApoE to LRP1 and LDLR [132].”
From ApoE lipoproteins in the central nervous system under homeostasis and role in Alzheimer’s disease and related disorders (2026) · cites this paper as [132]
ApoC1 inhibits binding of ApoE to LRP1 and LDLR.
“Apolipoprotein C1 (ApoC1) was found to be present at higher levels in ApoE2 and ApoE3 microglia secreted lipoproteins and is reported to inhibit binding of ApoE to LRP1 and LDLR [132].”
From ApoE lipoproteins in the central nervous system under homeostasis and role in Alzheimer’s disease and related disorders (2026) · cites this paper as [132]
ApoC1 inhibits binding of ApoE to LRP1 and LDLR.
“Compared to astrocytes, microglia lipoproteins contained higher levels of ApoC1, which inhibits binding of ApoE to LRP1 and LDLR (73).”
From Lipidome and proteome of astrocyte and microglia ApoE lipoprotein reveal differences based on cell type and ApoE isoform (2026) · cites this paper as [73]
Citations
Cites
A Receptor-Mediated Pathway for Cholesterol Homeostasis
Brown, M. S., & Goldstein, J. L. (1986) · Science · doi:10.1126/science.3513311 · Cited by 5,703
Vogel, T., Weisgraber, K. H., Zeevi, M. I., Ben-Artzi, H., Levanon, A. Z., Rall, S. C., Innerarity, T. L., Hui, D. Y., Taylor, J. M., & Kanner, D. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.24.8696 · Cited by 88
Flagged first, then by citations
Research works printed but not linked: 37
- Mahley, 1984, Adv. Intern. Med., 29, 385
- Gianturco, 1982, J. Lipid Res., 23, 984, 10.1016/S0022-2275(20)38070-6 · DOI
- Gianturco, 1983, J. Biol. Chem., 258, 4526, 10.1016/S0021-9258(18)32655-3 · DOI
- Wang-Iverson, 1985, Biochem. Biophys. Res. Commun., 126, 578, 10.1016/0006-291X(85)90645-X · DOI
- Krul, 1985, J. Clin. Invest., 75, 361, 10.1172/JCI111708 · DOI
- Bates, 1987, J. Lipid Res., 28, 787, 10.1016/S0022-2275(20)38647-8 · DOI
- Eisenberg, 1988, Arteriosclerosis, 8, 480, 10.1161/01.ATV.8.5.480 · DOI
- Friedman, 1990, Biochim. Biophys. Acta, 1044, 118, 10.1016/0005-2760(90)90226-N · DOI
- Sehayek, 1990, Arteriosclerosis, 9, 1088, 10.1161/01.ATV.10.6.1088 · DOI
- Yamada, 1989, Proc. Natl. Acad. Sci. U. S. A., 86, 665, 10.1073/pnas.86.2.665 · DOI
- Mahley, 1989, J. Clin. Invest., 83, 2125, 10.1172/JCI114126 · DOI
- Innerarity, 1978, Am. Chem. Soc., 17, 1440
- Pitas, 1979, Proc. Natl. Acad. Sci. U. S. A., 76, 2311, 10.1073/pnas.76.5.2311 · DOI · Paper page
- Fainaru, 1988, Arteriosclerosis, 8, 130, 10.1161/01.ATV.8.2.130 · DOI
- Albers, 1976, Artery, 2, 337
- Windier, 1980, J. Biol. Chem., 255, 8303, 10.1016/S0021-9258(19)70647-4 · DOI · Paper page
- Windier, 1985, J. Lipid Res., 26, 556, 10.1016/S0022-2275(20)34342-X · DOI
- Bilheimer, 1972, Biochim. Biophys. Acta, 260, 212, 10.1016/0005-2760(72)90034-3 · DOI
- Brown, 1970, Biochim. Biophys. Acta, 200, 573, 10.1016/0005-2795(70)90115-7 · DOI
- Lux, 1972, Biochim. Biophys. Acta, 278, 266, 10.1016/0005-2795(72)90231-0 · DOI
- Milne, 1981, J. Clin. Invest., 68, 111, 10.1172/JCI110225 · DOI
- Kleinman, 1985, J. Clin. Invest., 75, 1796, 10.1172/JCI111892 · DOI
- Bierman, 1974, Circ. Res., 35, 136, 10.1161/01.RES.35.1.136 · DOI
- Brown, 1975, Cell, 6, 307, 10.1016/0092-8674(75)90182-8 · DOI
- Goldstein, 1983, Methods Enzymol., 98, 241, 10.1016/0076-6879(83)98152-1 · DOI
- Lowry, 1951, J. Biol. Chem., 193, 265, 10.1016/S0021-9258(19)52451-6 · DOI
- Bartlett, 1959, J. Biol. Chem., 234, 466, 10.1016/S0021-9258(18)70226-3 · DOI
- Patsch, 1976, J. Lipid Res., 17, 182, 10.1016/S0022-2275(20)37004-8 · DOI
- Weber, 1969, J. Biol. Chem., 244, 4406, 10.1016/S0021-9258(18)94333-4 · DOI
- Havel, 1985, Arteriosclerosis, 5, 569, 10.1161/01.ATV.5.6.569 · DOI
- Borensztajn, 1984, Proc. Natl. Acad. Sci. U. S.A., 81, 5863, 10.1073/pnas.81.18.5863 · DOI
- Hertz, 1988, EMBO J., 7, 4119, 10.1002/j.1460-2075.1988.tb03306.x · DOI
- Beisiegel, 1989, Nature, 341, 162, 10.1038/341162a0 · DOI
- Kowal, 1989, Proc. Natl. Acad. Sci. U. S. A., 86, 5810, 10.1073/pnas.86.15.5810 · DOI
- Kowal, 1990, J. Biol. Chem., 265, 10771, 10.1016/S0021-9258(18)87014-4 · DOI · Paper page
- Weisgraber, 1990, J. Biol. Chem., 265, 22453, 10.1016/S0021-9258(18)45726-2 · DOI
- Eisenberg, 1972, Biochim. Biophys. Acta, 280, 94, 10.1016/0005-2760(72)90216-0 · DOI
Cited by
Sorted by citations
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308027 · Cited by 919
Diabetic dyslipidaemia: from basic research to clinical practice*
Taskinen, M.-R. (2003) · Diabetologia · doi:10.1007/s00125-003-1111-y · Cited by 888
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Gaudet, D., Alexander, V. J., Baker, B. F., Brisson, D., Tremblay, K., Singleton, W., Geary, R. S., Hughes, S. G., Viney, N. J., Graham, M. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1400283 · Cited by 528
Apolipoprotein C-III: understanding an emerging cardiovascular risk factor
Ooi, E. M. M., Barrett, P. H. R., Chan, D. C., & Watts, G. F. (2008) · Clinical Science · doi:10.1042/cs20070308 · Cited by 282
Wolska, A., Dunbar, R. L., Freeman, L. A., Ueda, M., Amar, M. J., Sviridov, D. O., & Remaley, A. T. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.10.025 · Cited by 231
Zheng, C., Khoo, C., Furtado, J., & Sacks, F. M. (2010) · Circulation · doi:10.1161/circulationaha.109.875807 · Cited by 223
Lee, S.-J., Campos, H., Moye, L. A., & Sacks, F. M. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000066131.01313.eb · Cited by 170
Willems van Dijk, K., Rensen, P. C., Voshol, P. J., & Havekes, L. M. (2004) · Current Opinion in Lipidology · doi:10.1097/00041433-200406000-00002 · Cited by 154
Mendivil, C. O., Zheng, C., Furtado, J., Lel, J., & Sacks, F. M. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.109.197830 · Cited by 145
Wyler von Ballmoos, M. C., Haring, B., & Sacks, F. M. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.05.002 · Cited by 134
Qin, W., Sundaram, M., Wang, Y., Zhou, H., Zhong, S., Chang, C.-C., Manhas, S., Yao, E. F., Parks, R. J., McFie, P. J., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.203679 · Cited by 107
Chunyu, Z., Christina, K., Katsunori, I., & Sacks, F. M. (2007) · Journal of Lipid Research · doi:10.1194/jlr.p600011-jlr200 · Cited by 95
An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor?
Chan, D. C., Chen, M. M., Ooi, E. M. M., & Watts, G. F. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01678.x · Cited by 85
Borén, J., Watts, G. F., Adiels, M., Söderlund, S., Chan, D. C., Hakkarainen, A., Lundbom, J., Lundbom, N., Matikainen, N., Kahri, J., et al. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.305614 · Cited by 72
Lee, S.-J., Moye, L. A., Campos, H., Williams, G. H., & Sacks, F. M. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00007-8 · Cited by 50
Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia
Renee Ruhaak, L., van der Laarse, A., & Cobbaert, C. M. (2019) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563219827620 · Cited by 38
Apolipoprotein CI Knock-Out Mice Display Impaired Memory Functions
Berbée, J. F. P., Vanmierlo, T., Abildayeva, K., Blokland, A., Jansen, P. J., Lütjohann, D., Gautier, T., Sijbrands, E., Prickaerts, J., Hadfoune, M., et al. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100576 · Cited by 25
Begcevic Brkovic, I., Zöhrer, B., Scholz, M., Reinicke, M., Dittrich, J., Kamalsada, S., Baber, R., Beutner, F., Teren, A., Engel, C., et al. (2022) · Nutrients · doi:10.3390/nu14122474 · Cited by 13
Strickland, M. R., Wang, Z., Golden, L. R., Wang, H., Lu, P., Ren, Y., Tabor, G. T., Zhao, N., Ulrich, J. D., Han, X., et al. (2026) · Journal of Lipid Research · doi:10.1016/j.jlr.2026.101000 · Cited by 8
Strickland, M. R., & Holtzman, D. M. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-026-00970-0
Metadata
- Authors
- Sehayek, E., & Eisenberg, S.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 1991-09
- Volume
- 266
- Issue
- 27
- Pages
- 18259-18267
- ISSN
- 0021-9258
- Cited by
- 249
- References
- 2
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review